Authors: Vincent E. de Meijer, Deanna Y. Sverdlov, Yury Popov, Hau D. Le, Jonathan A. Meisel, Vânia Nosé, Detlef Schuppan, Mark Puder
DOI: 10.1371/journal.pone.0011256
Abstract Summary
Marimastat, a drug blocking matrix metalloproteinases (MMPs) and inflammation-promoting enzymes, showed mixed results in liver fibrosis. While it reduced liver injury and inflammation in mice, collagen deposits increased 25%, worsening fibrosis. The drug’s anti-inflammatory benefits were offset by impaired collagen breakdown, accelerating disease progression. Researchers caution against using MMP inhibitors in chronic liver disease patients.
Why Brain? 🧠
MMP inhibitor Marimastat reduces liver inflammation but worsens fibrosis in mice by blocking collagen breakdown, suggesting caution when using MMP inhibitors in chronic liver disease patients.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
